Underlying growth is improving, but cell-therapy timing will remain a 300-basis-point Q3 headwind.
| Quarter | Q2 FY26 |
|---|---|
| Call date | 2026-02-04 |
| Length | 58 minutes |
| EPS | $0.39 |
| EPS consensus | $0.34 |
| Revenue | $295.9M |
What changed, guidance prior to now, analyst Q&A candor and the case for and against are part of Core.
Other quarters: Q3 FY26 · Q1 FY26 · Q4 FY25 · Q3 FY25
Read the full Q2 FY26 earnings call transcript
All TECH earnings · Back to TECH overview
Transcript produced by Signals.AI from the company's own earnings call audio. Not personalized investment advice.